Lakefront Biotherapeutics (formerly Galapagos) is a biopharmaceutical company that builds its pipeline largely by identifying, acquiring, and advancing clinical-stage therapeutic candidates. Historically rooted in European drug discovery and later cell therapy, it has shifted toward a deal-driven model focused on high-potential assets such as next-generation oncology approaches. It serves the biopharma development continuum rather than a single mass-market product franchise.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 65.3 | — | -105.8 | — |
| Q3 2025 | 71.2 | — | -202.1 | — |
| Q4 2025 | 900.8 | — | 782.1 | — |
| Q1 2026 | 6.5 | — | 14.5 | — |
| Q2 2026 | 12.1 | -81.5% | 2.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Blue Bird Corporation (BLBD), Pharvaris N.V. (PHVS), Immunome, Inc. (IMNM), Trump Media & Technology Group Corp. (DJT), nLIGHT, Inc. (LASR), eToro Group Ltd. (ETOR)